Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Targeted therapy of short-bowel syndrome with teduglutide: the new kid on the block.

Vipperla, Kishore and O'Keefe, Stephen J (2014) Targeted therapy of short-bowel syndrome with teduglutide: the new kid on the block. Clin Exp Gastroenterol, 7. 489 - 495. ISSN 1178-7023

Published Version
Available under License : See the attached license file.

Download (212kB)
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Extensive intestinal resection impairs the absorptive capacity and results in short-bowel syndrome-associated intestinal failure (SBS-IF), when fluid, electrolyte, acid-base, micro-, and macronutrient homeostasis cannot be maintained on a conventional oral diet. Several factors, including the length and site of the resected intestine, anatomical conformation of the remnant bowel, and the degree of postresection intestinal adaptation determine the disease severity. While mild SBS patients achieve nutritional autonomy with dietary modification (eg, hyperphagia, small frequent meals, and oral rehydration fluids), those with moderate-to-severe disease may develop SBS-IF and become dependent on parenteral support (PS) in the form of intravenous fluids and/or nutrition for sustenance of life. SBS-IF is a chronic debilitating disease associated with a poor quality of life, and carries significant morbidity and health care costs. Medical management of SBS-IF is primarily focused on individually tailored symptomatic treatment strategies, such as antisecretory and antidiarrheal agents to mitigate fluid losses, and PS. However, PS administration is associated with potentially life-threatening complications, such as central venous thromboses, bloodstream infections, and liver disease. In pursuit of a targeted therapy to augment intestinal adaptation, research over the past 2 decades has identified glucagon-like peptide, an intestinotrophic gut peptide that has been shown to enhance intestinal absorptive capacity by causing an increase in the villus length, crypt depth, and mesenteric blood flow and by decreasing gastrointestinal motility and secretions. Teduglutide, a recombinant analog of glucagon-like peptide-2, is the first targeted therapeutic agent to gain approval for use in adult SBS-IF. Teduglutide was shown to result in significant (20%-100%) reduction in PS-volume requirement and have a satisfactory safety profile in three randomized control trials. Further research is warranted to see if reduction in PS dependency translates to improved quality of life and reduced PS-associated complications.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Vipperla, Kishore
O'Keefe, Stephen J
Date: 2014
Date Type: Publication
Journal or Publication Title: Clin Exp Gastroenterol
Volume: 7
Page Range: 489 - 495
DOI or Unique Handle: 10.2147/ceg.s42665
Refereed: Yes
Uncontrolled Keywords: glucagon-like peptide-2, intestinal adaptation, short-gut syndrome, teduglutide
ISSN: 1178-7023
Date Deposited: 09 Apr 2015 18:54
Last Modified: 20 Dec 2018 00:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item